Mergers & Acquisitions


Current filters:


Popular Filters

826 to 850 of 919 results

French biotechnology a sector in need of new growth solutions


The biotechnology industry in France is a dynamic sector mainly made up of small structures, but companies…

BiotechnologyEuropeFinancialMergers & Acquisitions

Agilent to acquire cancer diagnostics firm Dako for $2.2 billion


USA-based Agilent Technologies (NYSE: A) and EQT, a Swedish private equity group, have entered into an…

AgilentDakoMergers & AcquisitionsOncologyPharmaceutical

Human Genome adopts Rights Plan to thwart GSK hostile takeover


US biotech company Human Genome Sciences (Nasdaq: HGSI) said yesterday that, after carefully reviewing…

BiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

GlaxoSmithKline buys full control of Cellzome


UK pharma giant GlaxoSmithKline (LSE: GSK) has signed an agreement to fully acquire privately held Cambridge…

BiotechnologyCellzomeGlaxoSmithKlineMergers & AcquisitionsPharmaceutical

Cornerstone makes $125 million, plus, bid for EKR Thera


In a second acquisition move within a matter of months, USA-based specialty drugmaker Cornerstone Therapeutics…

Cardio-vascularCornerstone TherapeuticsEKR TherapeuticsMergers & AcquisitionsPharmaceutical

Empty pipelines drive deal valuations in pharmaceuticals sector, say IMAP


A drought of domestic growth opportunities and new products is inflating valuations for R&D companies…

BiotechnologyMergers & AcquisitionsPharmaceuticalResearch

Life sciences M&A activity heats Up in April, says Burrill & Co


April proved to be a big month for M&A activity in the life sciences as companies announced more than…

BiotechnologyFinancialMergers & AcquisitionsPharmaceutical

Valeant Pharma to acquire assets from University Medical; posts 1st-qtr loss


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has agreed to…

FinancialMergers & AcquisitionsPharmaceuticalUniversity Medical PharmaValeant Pharmaceuticals

Novartis to buy US generic derma company Fougera for over $1.5 billion


Further expanding its generic drug foot print, Swiss drug giant Novartis (NOVN: VX) is adding to its…

DermatologicalsFougera PharmaceuticalsGenericsMergers & AcquisitionsNovartisPharmaceuticalSandoz

Gen-Probe agrees $3.7 billion acquisition by Hologic


USA-based Hologic (Nasdaq: HOLX) said it has reached an agreement to acquire Gen-Probe (Nasdaq: ASDAQ)…

Gen-ProbeHologicMergers & AcquisitionsPharmaceutical

Haemonetics to buy Pall Corp blood collection and processing lines for $550 million; and Hemerus Medical


USA-based Pall Corp (NYSE: PLL) has entered into an agreement to sell certain assets of its blood collection,…

HaemoneticsHemerus MedicalMergers & AcquisitionsPall CorpPharmaceutical

Jazz Pharma to acquire EUSA Pharma for up to $700 million


US drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) said last week that it has signed a definitive accord…

EUSA PharmaJazz PharmaceuticalsMergers & AcquisitionsPharmaceutical

Global generic drug markets will grow to $221 billion by 2016; Espicom


The economic recession has been a double-edged sword for the international generic drugs business. Driven…

GenericsGlobalMarkets & MarketingMergers & AcquisitionsPricing

Amylin operating loss leaps to over $30 million


US biotech firm Amylin Pharmaceuticals (Nasdaq AMLN): reported financial results for the quarter ended…

AmylinBiotechnologyFinancialMergers & Acquisitions

Fitch puts Watson on rating watch Negative on planned acquisition of Actavis


US generics drugmaker Watson Pharmaceuticals (NYSE: WPI) has seen its rating downgraded by Fitch Ratings,…

ActavisFinancialGenericsMergers & AcquisitionsNorth AmericaWatson Pharmaceuticals

Watson Pharma confirms buy of generic group Actavis for 4.25 billion euros


As has been widely rumoured over this week, Watson Pharmaceuticals (NYSE: WPI) has confirmed a definitive…

ActavisGenericsMergers & AcquisitionsWatson Pharmaceuticals

Amgen acquires Turkish drugmaker Mustafa Nevzat for $700 million


Global biotech giant Amgen (Nasdaq: AMGN) has reached agreement to acquire 95.6% of Mustafa Nevzat Pharmaceuticals…

AmgenBiotechnologyMergers & AcquisitionsMustafa Nevzat PharmaPharmaceutical

Biota and Nabi announce proposed merger


Australian firm Biota Holdings (ASX: BTA) and USA-based Nabi Biopharmaceuticals (Nasdaq: NABI) yesterday…

Biota HoldingsBiota PharmaceuticalsBiotechnologyMergers & AcquisitionsNabi BiopharmaceuticalsPharmaceutical

826 to 850 of 919 results




Back to top